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Background: Surgical revascularization for lower limb ischemia remains an important component for optimization of
quality of life and symptoms in patients with peripheral arterial disease. In the absence of a vein graft, prosthetic alternatives
are considered. The objective of this meta-analysis was to establish which prosthetic graft, Dacron or polytetraﬂuroethylene
(PTFE), has the better long-term patency in patients undergoing an above-knee femoropopliteal arterial bypass.
Methods: This meta-analysis was performed by use of Cochrane and Preferred Reporting Items for Systematic Reviews and
Meta-Analyses guidelines. An electronic search of all relevant databases was performed from 1990 to 2013 with the
Medical Subject Headings “Dacron,” “polytetraﬂuroethylene,” “PTFE,” “above knee,” “femoropopliteal,” and “bypass”
combined with the Boolean operator “AND.” The inclusion criteria were randomized controlled trials, use of Dacron vs
PTFE prosthetic conduits, and completion of an above-knee femoropopliteal arterial bypass involving adult patients older
than 18 years presenting with disabling claudication, rest pain or tissue loss, occlusion of the superﬁcial femoral artery,
and reconstitution of the above-knee popliteal artery. Whenever studies included above- and below-knee data, only the
above-knee arterial bypass data were extracted and analyzed. Graft patency rates were calculated with RevMan 5.1
software provided by the Cochrane Collaboration.
Results: Ninety-one publications were reviewed. After exclusion of duplicate, nonrandomized, and alternative bypass
surgery studies, eight randomized controlled trials were identiﬁed and included in the meta-analysis. Two of the included
trials represented follow-up evaluation of two previous studies, and for the purpose of this analysis, the initial and follow-
up studies were subsequently evaluated as one trial. In this meta-analysis, 1192 patients were assessed, including 601
Dacron and 591 PTFE above-knee lower limb arterial bypasses. Primary patency was calculated from all included studies.
However, only four studies provided data to evaluate secondary patency. Mean age reported was 66 years. Although all
studies described cardiovascular comorbidities and risk factors including myocardial ischemia, diabetes, hypertension, and
smoking, exact patient numbers were not consistently provided. Included studies evaluated grafts from 5 to 8 mm.
Although primary and secondary patency rates at 12 months were not signiﬁcantly different (relative risk [RR], 0.78; P[
.08, andRR, 0.84; P[ .52), 24-, 36-, and 60-month primary patency rates were signiﬁcantly better withDacron compared
with PTFE grafts (RR, 0.79; P[ .003; RR, 0.80; P[ .03; RR, 0.85; P[ .02). Statistical analysis also supported higher
secondary patency rates for Dacron at 24 months (RR, 0.75; P [ .02) and 60 months (RR, 0.76-0.77; P [ .03-.27).
Although primary patency was similar between grafts (28% vs 28%; P[ .12), secondary patencies were better with Dacron
at 10 years (49% vs 35%; P [ .01). Antiplatelet and anticoagulation protocols varied between the trials. There was no
difference in amputation, overall morbidity, or mortality rates between the two surgical graft populations.
Conclusions: Current evidence suggests that Dacron prosthetic grafts are superior to PTFE grafts in above-knee femo-
ropopliteal arterial bypass procedures. Further randomized trials targeting standardization of confounding variables,
particularly graft size and best medical therapy, are warranted. (J Vasc Surg 2014;60:506-15.)the Department of Vascular and Endovascular Surgery, Royal Victoria
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Volume 60, Number 2 Rychlik et al 507Peripheral arterial disease, deﬁned as the presence of
atherosclerosis distal to the aortic bifurcation, affects be-
tween 12% and 20% of patients older than 60 years, ac-
counting for an estimated 27 million people affected in
North America and Europe.1,2 Claudication is deﬁned as
reproducible lower extremity muscle pain reﬂecting the
symptomatic expression of the inability of the lower limb
musculature to maintain adequate perfusion and oxygena-
tion during exertional activity. Claudication symptoms
progress in 25% of all those affected, with deterioration at
rates of 7% to 9% in the ﬁrst year and then subsequently
at rates of 2% to 3% per year. Disease progression to critical
limb ischemia may be manifested with rest pain or tissue
loss with an incidence of 0.25 to 0.45 per 1000 people
per year.3
Although endovascular modalities are increasingly
used, surgical revascularization for lower limb ischemia still
remains an important component for optimization of qual-
ity of life and symptoms in those patients with claudication
while preventing tissue or limb loss in more advanced cases
of critical limb ischemia. Myriad different bypass conduits,
including autologous, homologous, and prosthetic grafts,
are currently available. Superiority of vein graft is well
established and remains the “gold standard” conduit for
vascular reconstruction.4-6 The Cochrane review by Twine
and McLain7 in 2010 reported better primary patency rates
with autologous vein compared with polyester (Dacron),
polytetraﬂuroethylene (PTFE), and human umbilical vein
for above-knee femoropopliteal arterial bypass grafts.
However, despite the advantages of autologous vein, a
prosthetic graft may be considered an alternative in the
absence of a suitable vein conduit or in the presence of
certain patient comorbidities. Although previous studies
have reported the efﬁcacy of above-knee prosthetic arterial
bypass grafts, few have speciﬁcally compared the different
prosthetic materials, addressed long-term prosthetic graft
patency rate and limb salvage outcomes, or provided strict
protocols for best medical therapy, especially the role of an-
tiplatelet and anticoagulation therapy. Indeed, Twine and
McLain7 have suggested a requirement for more random-
ized data to explore actual improvements in limb salvage
for each of the prosthetic bypass conduits. A deﬁnitive
consensus regarding the role and type of prosthetic graft
for above-knee arterial bypass remains unclear. The main
objective of this meta-analysis and systematic review was
to investigate long-term patency of Dacron and PTFE
prosthetic grafts after above-knee femoropopliteal arterial
bypass.
METHODS
This meta-analysis was performed by use of standard
guidelines outlined in the Cochrane Handbook for System-
atic Reviews of Interventions (version 5.1.0) and the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement.8,9
Search strategy and study selection. The authors
performed the literature search with the following elec-
tronic resources: PubMed, Cochrane Central Register ofControlled Trials, and ClinicalTrials.gov. The search was
completed with the Medical Subject Headings “Dacron,”
“polytetraﬂuroethylene,” “PTFE,” “above knee,” “femo-
ropopliteal,” and “bypass” combined with the Boolean
operator “AND.” We did not apply language limitations
to our search. The authors considered all studies published
from 1990 to 2013. Potentially relevant publications and
comparative studies of Dacron vs PTFE were retrieved.
We have also reviewed references of all comparative
research to identify any further potential studies, which
were subsequently evaluated.
Inclusion and exclusion criteria. The inclusion
criteria for this meta-analysis were randomized controlled
trials, use of Dacron vs PTFE prosthetic conduits, and
completion of an above-knee femoropopliteal arterial
bypass involving adult patients older than 18 years pre-
senting with disabling claudication, rest pain or tissue loss,
occlusion of the superﬁcial femoral artery, and reconstitu-
tion of the above-knee popliteal artery. We also included
lower limb arterial bypass studies when we were able to
extract data for supragenicular bypass. Nonrandomized
clinical trials or other comparative studies and research
assessing other conduits for above-knee femoropopliteal
artery bypass or more distal arterial bypasses were excluded
from further analysis, as were patients with a history of
previous femoropopliteal bypass, less than 1 year of life
expectancy, lower extremity oncologic treatment with
radiotherapy or chemotherapy, and no valid informed
consent documentation.
Data extraction. All data were extracted indepen-
dently by two authors (I.J.R. and P.D.) by a speciﬁcally
designed data collection pro forma that allowed a list of
all relevant information from each study, including the
year of publication, study design, inclusion criteria, exclu-
sion criteria, type of graft used, number of participants in
each group, patency rates, use of antiplatelet and anticoag-
ulant therapy, and failure of procedures. The primary out-
comes for this meta-analysis included primary and
secondary graft patency rates at 12 months, 24 months,
36 months (primary only), 5 years, and 10 years. Secondary
outcome measures included an assessment of antiplatelet
and anticoagulation strategies, limb loss rates, and overall
morbidity and mortality.
Assessment of risk of bias. The Cochrane Collabora-
tion’s tool for assessing risk of bias was used to assess the qual-
ity of the randomized controlled trials included in this meta-
analysis independently by two raters (I.J.R. and P.D.).8 This
included random sequence generation; allocation conceal-
ment; blinding; and assessment of outcome, incomplete data,
selective reporting, and other sources of bias.
Statistical analysis. The meta-analysis was performed
with the RevMan 5.2 tool provided by the Cochrane
Collaboration (http://ims.cochrane.org/revman). All the
assessed variables were dichotomous. Statistical analysis was
performed by the Mantel-Haenszel test. We used risk ratio
(RR) as the summary statistic with corresponding 95%
conﬁdence intervals (CIs). Pearson c2 test was used to
assess statistical heterogeneity where signiﬁcance was set at
Fig 1. Study ﬂow diagram according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines. RCT, Randomized controlled trial.
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above 50% indicated important statistical heterogeneity.
The random-effects model was then employed when there
was signiﬁcant heterogeneity. The meta-analysis was
completed with a ﬁxed-effects model and a random-effects
model for each outcome. These analyses were subsequently
compared, and where there was no difference between the
two, we used the ﬁxed-effects model. Both models were
presented if there was inconsistency between results. A
P value < .05 was considered statistically signiﬁcant.
RESULTS
After review of all relevant literature by use of the
PRISMA guidelines,9 eight randomized controlled trials
were identiﬁed and included in the meta-analysis (Fig 1
and Table).
Patient demographics
In this meta-analysis assessing Dacron vs PTFE grafts
for above-knee lower limb arterial bypasses, 1192 patients
were subsequently included; 601 underwent procedures
with Dacron, and 591 were treated with PTFE grafts.
Mean age reported was approximately 66 years.10-15
Although exact comorbidity data could not be further
analyzed in this meta-analysis because of inconsistencies
in the included studies, it is recognized that most studiesincluded a patient population with generalized cardiovas-
cular comorbidities and risk factors including myocardial
ischemia, diabetes, hypertension, and smoking.10-17
Graft type
Davidovic et al10 compared the use of 8-mm collagen-
coated Dacron with 8-mm expanded PTFE grafts for
above-knee femoropopliteal arterial bypasses. van Det
et al11 assessed the long-term patency of 6-mm collagen-
impregnated Dacron and expanded PTFE vascular grafts,
whereas Jensen et al12 compared 6-mm gelatin-coated
Dacron and expanded PTFE grafts for patients undergoing
above-knee femoropopliteal arterial bypass for chronic lower
limb ischemia. Post et al13 assessed patency of unsealed knit-
ted polyester velour grafts and thin-walled PTFE grafts for
above-knee surgery with diameter ranging from 6 to
8 mm. Devine et al14,15 compared collagen-coated hepa-
rin-bonded Dacron and PTFE. Although the authors used
predominantly 6-mm grafts, they did not specify exact pa-
tient numbers. Abbott et al16 and Green et al17 investigated
patency rates between collagen-impregnated Dacron and
expanded PTFE grafts used for above-knee femoropopliteal
arterial reconstructions in patients with arteriographically
proven occlusion of the superﬁcial femoral artery and recon-
stitution of the popliteal artery above the knee.However, the
decision pertaining to the size of the graft was left to the
JOURNAL OF VASCULAR SURGERY
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summary, three of the included studies compared the same
size of prosthetic graft type as stated in the original clinical
trial study protocol. Two studies evaluated 6-mm grafts,
and one study assessed 8-mm grafts; in the other study, the
graft size ranged between 5 and 8 mm.
Operative data
The most recent study by Davidovic et al10 assessed 85
patients with disabling claudication and critical ischemia
whowere recruited to a bicenter randomized controlled trial
directly comparing 8-mm collagen-coated Dacron (n¼ 42)
with 8-mm expanded PTFE (n¼ 43) for above-knee femo-
ropopliteal grafts. The main indication for surgery was crit-
ical limb ischemia, which occurred more commonly in the
Dacron group (71.4% vs 69.7%). At 12-month follow-up,
primary graft patency was signiﬁcantly better in the Dacron
group (100%) compared with the PTFE group (88.4%) (P<
.05). However, there was no difference in secondary graft
patency rates (83.3% vs 75%; P > .05). There was no infor-
mation as to whether any additional vascular procedures
were performed during the main surgery. Additional ﬁnd-
ings from their study suggested that single-vessel crural
runoff signiﬁcantly reduced prosthetic graft patency, more
so in the Dacron group than in the PTFE group (P < .05).
van Det et al11 assessed the long-term patency of 6-mm
collagen-impregnated Dacron (n ¼ 114) and expanded
PTFE (n ¼ 114) vascular grafts used during standardized
above-knee femoropopliteal arterial bypasses performed
for disabling claudication, rest pain, or tissue loss. These
authors did not report any signiﬁcant difference in relation
to indications for surgery for the two graft groups (P ¼
.94). There was no comment on additional procedures per-
formed during the main surgical procedure. They reported
signiﬁcantly higher 5-year primary and secondary graft pa-
tencies for the Dacron grafts compared with PTFE (52% vs
36%, P ¼ .04 and 70% vs 51%, P ¼ .01). However, primary
patency for the groups appeared to converge at 10-year
follow-up despite maintenance of improved secondary
patency for the Dacron group (49% vs 35%; P ¼ .01).
Jensen et al12 published a series of 427 randomized pa-
tients undergoing above-knee femoropopliteal arterial
bypass for chronic lower limb ischemia with 6-mm gelatin-
coated Dacron (n ¼ 208) or 6-mm expanded PTFE (n ¼
205) grafts. One patient did not proceed to surgery, whereas
13 others were excluded because of randomization errors,
missing postoperative data, or absence of valid patient iden-
tiﬁcation data. Primary and secondary graft patencies at
24 months were signiﬁcantly better in the Dacron group
than in the PTFE group (70% vs 57%, P ¼ .02 and 76% vs
65%, P¼ .04). These authors reported a trend toward better
patency in claudicants compared with critically ischemic pa-
tients (65% vs 59%; P¼ not signiﬁcant). The authors did not
comment on concomitant procedures. Subgroup analysis
suggested that the number of patent runoff vessels inﬂu-
enced midterm patency rates. Patients with more than one
crural vessel performed better than those with only one pat-
ent runoff vessel (67% vs 50%; P ¼ .01).Devine et al14,15 assessed 209 patients who were fol-
lowed up for a period of at least 5 years. Results were re-
ported in two separate publications. As these authors
included both above- and below-knee procedures, speciﬁc
analysis was not possible, but we were able to extract the
data for supragenicular surgery and to assess primary
patency. Ninety-one patients underwent above-knee
surgery with use of Dacron graft, and 88 had a PTFE pros-
thesis. There was no comment on additional recanalization
procedures. Secondary patency and other outcomes were
presented for the overall population; therefore, we did
not include these data because our main focus was
above-knee surgery. P values were not available for 12-
and 24-month follow-up. Follow-up at 36 months revealed
signiﬁcantly better patency of Dacron material (P ¼ .037).
Five-year primary patency for the Dacron and PTFE
groups was 50% vs 41% (P ¼ .14).
Post et al13 investigated patency of Dacron and thin-
walled PTFE for above-knee grafts in 203 patients. This
study also included below-knee procedures. Therefore,
as for the studies of Devine et al,14,15 we had to extract
the above-knee data to perform our meta-analysis. Sev-
enty-six patients received Dacron and 65 had PTFE
grafts. Subgroup analyses of primary patency for suprage-
nicular procedures were 80% vs 71%, 75% vs 65%, and
70% vs 62% at 12, 24, and 36 months of follow-up for
the Dacron and PTFE groups (P ¼ .35). Although study
inclusion allowed any type of inﬂow reconstruction, exact
speciﬁcs were not detailed. We were unable to comment
on secondary patency as this result was given for the over-
all group.
Further published studies have failed to elicit any dif-
ference between the two prosthetic conduits. Abbott
et al16 and Green et al17 investigated patency rates be-
tween collagen-impregnated Dacron and expanded
PTFE grafts used for above-knee femoropopliteal arterial
reconstructions in patients with arteriographically proven
occlusion of the superﬁcial femoral artery and reconstitu-
tion of the popliteal artery above the knee. Eligible pa-
tients with claudication, rest pain, or ischemic tissue
loss were enrolled between 1991 and 1996. Critical
limb ischemia was an indication in 38% of the Dacron
population and in 37% of the PTFE group, and the au-
thors commented that this difference was not signiﬁcant
(no P value available). The operator determined graft
diameter and postoperative anticoagulation regimen.
Iliac angioplasty and iliofemoral bypasses were permitted
as an additional procedure. This multicenter randomized
trial did not demonstrate any signiﬁcant difference be-
tween the grafts for 3-year primary patency rates (62%
vs 58%; P value not stated) and overall secondary patency
rates (75% vs 75%; P value not stated). There was also no
signiﬁcant difference at 5-year follow-up, when primary
patency was 45% for Dacron and 43% for PTFE. Simi-
larly, there was no difference in secondary patency, which
was 68% in both groups. Interestingly, subgroup analyses
suggested that smaller graft sizes of 5 or 6 mm were sig-
niﬁcant predictors of graft occlusion (P ¼ .0006). This
Table. Details of randomized controlled trials included in meta-analysis
Author, date, and
country Patient group Type of study Outcomes
Key results Dacron vs
PTFE Notes
Davidovic et al,10
2010
Serbia
85 patients with
disabling
claudication or
critical limb
ischemia suitable
for above-knee
reconstruction
were randomized
to Dacron (n ¼
42) and expanded
PTFE (n ¼ 43).
Prospective
randomized
clinical trial
Primary graft
patency
100% vs 88.37%
(P < .05)
This study suggested that
primary patency might be
better for the Dacron grafts.
However, in patients with
only one patent crural
vessel, the authors noticed
decreased patency of both
grafts and favored the use of
PTFE graft (P < .05) There
was no signiﬁcant difference
in secondary patency
between groups. All patients
received aspirin
postoperatively.
Secondary graft
patency
83.3% vs 75%
(P > .05)
van Det et al,11
2009
The Netherlands
228 patients were
randomly allocated
to expanded PTFE
group (n ¼ 114)
and Dacron group
(n ¼ 114). Patients
presenting with
disabling
claudication, rest
pain, or tissue loss
who underwent
above-knee arterial
bypass were
included.
Prospective
randomized
clinical trial
Primary graft
patency
At 2 years: 70% vs 64%
(P ¼ .38)
At 5 years: 52% vs 36%
(P ¼ .04)
At 10 years: 28% vs. 28%
(P ¼ .12)
The authors of this study
followed up the patients for
the longest time. They used
the same size graft in both
groups. The 5-year patency
was signiﬁcantly better in
the Dacron group, in
primary as well as in
secondary patency patients.
The 10-year follow-up
revealed similar primary
patency in both groups;
however, secondary patency
was again signiﬁcantly better
in the Dacron group. All
patients were prescribed
warfarin after surgery.
Secondary graft
patency
At 2 years: 84% vs 78%
(P ¼ .31)
At 5 years: 70% vs 51%
(P ¼ .01)
At 10 years: 49% vs 35%
(P ¼ .01)
Jensen et al,12
2007
Denmark
427 patients
presenting with
chronic lower limb
ischemia were
included in this
study; 208 patients
were randomized
to Dacron group,
205 to PTFE
group; 14 were
excluded.
Prospective
randomized
clinical trial
Primary graft
patency
At 2 years: 70% vs 57%
(P ¼ .02)
This study showed superiority
of Dacron graft vs PTFE in
patients after above-knee
femoropopliteal bypass. The
authors also found that the
number of outﬂow vessels
had a signiﬁcant impact on
the graft patency; 67% of
patients with more than one
crural vessel had patent graft
(P ¼ .01).
Secondary graft
patency
At 2 years: 76% vs 65%
(P ¼ .04)
Abbott et al,16
1997
Green et al,17
2000
United States
244 patients were
randomized.
Sufﬁcient data
were available for
231 patients
presenting with
claudication,
ischemic rest pain,
or tissue loss.
Prospective
randomized
clinical trial
Primary graft
patency
(P values not signiﬁcant,
exact value not
available for all data
sets)
At 1 year: 74% vs 76%
At 2 years: 63% vs 65%
At 3 years: 62% vs 58%
At 5 years: 45% vs 43%
This trial did not demonstrate
any signiﬁcant difference in
graft patency between the
two groups. Patients
underwent supragenicular
procedures only. There was
no determined graft size.
The authors reported that a
small graft size (5-6 mm)
was a signiﬁcant predictor of
graft failure (P ¼ .0006)
The study by Green et al
added 5-year follow-up
results.
No details are available on
anticoagulation therapy.
Secondary graft
patency
(P value not signiﬁcant,
exact value not
available)
At 1 year: 88% vs 88%
At 2 years: 80% vs 80%
At 3 years: 75% vs 75%
At 5 years: 68% vs 68%
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Table. Continued.
Author, date, and
country Patient group Type of study Outcomes
Key results Dacron vs
PTFE Notes
Post et al,13 2001
Germany
203 patients were
randomized in
total. These
included above-
and below-knee
bypasses. Data
were extracted for
above-knee
patients and
included 76
patients who had
Dacron prosthesis
and 65 who had
PTFE.
Prospective
randomized
clinical trial
Primary graft
patency
(P value not available for
all of the data as
patency rates were
extracted from overall
results; however, it
was commented as not
signiﬁcant.)
At 1 year: 80% vs 71%
At 2 years: 75% vs 65%
At 3 years: 70% vs 62%
(P ¼ .35)
The study by Post et al did not
show statistically signiﬁcant
differences between both
groups. However, these
included above- and below-
knee bypasses. We were able
to extract data for above-
knee bypasses, for which the
authors did not ﬁnd
signiﬁcant differences in
graft patency between the
two surgical grafts.
Multivariate analysis revealed
that below-knee
anastomosis was the
independent predicting
factor of primary graft
failure (RR, 1.7; CI, 1.05-
2.8). Impaired secondary
patency was associated with
a below-knee bypass RR of
3.3 (CI, 1.8-6.3) and distal
gangrene RR of 2.0 (CI,
1.01-3.8; P ¼ .048). Major
amputation was predicted
by infragenicular bypass,
tissue necrosis, and poor
runoff.
Postoperatively, patients
received antiplatelet therapy,
heparin, or warfarin. This
was not standardized.
Devine et al,14,15
2001, 2004
United Kingdom
209 patients were
randomized to
receive bypass
surgery. The study
included above-
and below-knee
procedures. Data
were extracted for
above-knee
surgery to allow
statistical analysis.
This included 91
heparin-bonded
Dacron prostheses
and 88 PTFE
grafts.
Prospective
randomized
controlled
trial
Primary graft
patency
(P value not available for
all the data patency
rates were extracted
from overall results;
however, it was
commented as not
signiﬁcant.)
1 year: 76% vs 66%
2 years: 65% vs 52%
3 years: 61% vs 46%
(P ¼ .037)
5 years: 50% vs 41%
(P < .142)
Devine et al published their
results in two data sets. They
reported signiﬁcantly better
patency rates with Dacron
than with PTFE at 3 years
(P < .044), but the
difference was no longer
statistically signiﬁcant at
5 years (P < .055). Major
limb amputation was higher
(P < .025) in the PTFE
group compared with the
Dacron group at 3 and
5 years of follow-up. These
results apply to overall data,
which include above- and
below-knee data.
All patients received 300 mg of
aspirin postoperatively
unless contraindicated.
There was no comment on
alternative treatment if this
was the case.
CI, Conﬁdence interval; RR, relative risk; PTFE, polytetraﬂuoroethylene.
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.001).
Primary outcome measures
Primary patency rates at 12 months. Primary
patency rates at 12 months were documented in fourstudies; Davidovic et al reported a signiﬁcant advantage
with Dacron, whereas Abbott/Green et al, Post et al,
and Devine et al did not show statistically signiﬁcant
difference between the two prosthetic conduits.10,14-17
Our meta-analysis revealed low heterogeneity (I2 ¼ 31%)
between these studies, and therefore a ﬁxed-effects model
Fig 2. Meta-analysis of primary patency rates for 12, 24, and 36 months and 5 years by ﬁxed-effects Mantel-Haenszel
(M-H) model. CI, Conﬁdence interval; PTFE, polytetraﬂuoroethylene.
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Dacron group, which did not reach signiﬁcant difference
(RR, 0.78; 95% CI, 0.59-1.03; P ¼ .08) (Fig 2).
Primary patency rates at 24 months. Patency rates at
24 months were described in ﬁve of the randomized
controlled trials reviewed. Jensen et al and van Det et al re-
ported better patency with Dacron, whereas Abbott/Green
et al, Post et al, and Devine et al identiﬁed no signiﬁcant dif-
ference between Dacron and PTFE.11-17 Fixed model re-
sults due to absence of heterogeneity from ourmeta-analysis
revealed a signiﬁcant difference in favor of the Dacron graft
(RR, 0.79; 95% CI, 0.68-0.92; P ¼ .003) (Fig 2).
Primary patency rates at 36 months. Patency
results at 36 months were published in three studies.14-17Abbott/Green et al and Post et al did not show signiﬁ-
cant differences between the two graft materials. Devine
et al revealed signiﬁcantly better performance with the
Dacron graft (61% vs 46%; P ¼ .037). Fixed model results
showed signiﬁcantly better outcome in the Dacron group
(RR, 0.80; 95% CI, 0.65-0.98; P ¼ .03) (Fig 2).
Primary patency rates at 5 and 10 years. van Det
et al, Devine et al, and Abbott/Green et al reported 5-
year primary patency rates.11,14-17 Only the ﬁrst one of
this group showed signiﬁcantly improved patency rates of
Dacron compared with PTFE (52% vs 36%; P ¼ .04). The
remaining studies did not show signiﬁcant differences.
Patency reported in the study of Abbott/Green et al was
45% vs 43% (P value stated as not signiﬁcant), whereas
Fig 3. Meta-analysis of secondary patency rate for 12 and 24 months by ﬁxed-effects Mantel-Haenszel (M-H) model.
CI, Conﬁdence interval; PTFE, polytetraﬂuoroethylene.
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for PTFE (P < .142). Our meta-analysis, however, revealed
a signiﬁcant advantage with Dacron (RR, 0.85; 95% CI,
0.74-0.98; P ¼ .02) (Fig 2). van Det et al also reported no
signiﬁcant difference in primary patency rate between graft
types at 10 years (28% vs 28%; P ¼ .12).
Secondary patency. Secondary patency rates were
calculated for only ﬁve of the included studies.10-12,16,17
Three publications that included below-knee procedures
presented only combined patency data inclusive of above-
and below-knee procedures.13-15
Secondary patency rates at 12 months. Davidovic
et al and Abbott/Green et al described 12-month second-
ary patency rates.10,16,17 Our meta-analysis did not show a
statistically signiﬁcant difference between the two graft
materials (RR, 0.84; 95% CI, 0.49-1.44; P ¼ .52) (Fig 3).
Secondary patency rates at 24 months. Three ran-
domized controlled trials by van Det et al, Jensen et al,
and Abbott/Green et al assessed secondary patency at
24 months.11,12,16,17 Statistical analysis supports a higher
patency rate for Dacron compared with PTFE grafts (RR,
0.75; 95% CI, 0.59-0.95; P ¼ .02) (Fig 3).
Secondary patency rates at 5 and 10 years. van Det
et al11 reported a signiﬁcant beneﬁt in secondary patency at
5 years with Dacron grafts (70% vs 51%; P ¼ .01). Abbott/
Green et al16,17 did not see this difference in their study, in
which reported patency was 68% for both materials (P
value stated as not signiﬁcant). Our meta-analysis sug-
gested signiﬁcant heterogenicity between these studies, and
therefore we present both ﬁxed and random model results,
which identiﬁed a signiﬁcant beneﬁt with Dacron (RR,
0.76; 95% CI, 0.59-0.97; P ¼ .03) in the former analysis
and no difference in the latter analysis (RR, 0.77; 95% CI,
0.43-1.23; P ¼ .27) (Fig 4). van Det et al11 demonstratedcontinued secondary patency superiority with Dacron at
10-year follow-up as well (49% vs 35%; P ¼ .01).
Secondary outcome measures
Antiplatelet and anticoagulation treatment. Anti-
platelet and oral anticoagulation therapies were adminis-
tered in 82% and 3% of postoperative patients by Jensen
et al.12 In the study by van Det et al,11 all patients were
prescribed warfarin postoperatively, although there is no
comment on follow-up or monitoring. Devine et al14,15
administered 300 mg of aspirin. No speciﬁed antiplatelet
therapy, heparin, or warfarin was used by Post et al.13
Davidovic et al10 used aspirin in their patients. Abbott/
Green et al16,17 deferred the decision pertaining to the use
of antiplatelet or anticoagulation therapy to the operating
surgeon. Unfortunately, secondary prevention in the
included studies varied and did not permit further analysis.
Limb loss. Davidovic et al10 documented seven am-
putations at the end of their follow-up, with no signiﬁcant
difference between the grafts (P > .05). All amputations
were performed in patients who required lower limb
revascularization for critical ischemia. van Det et al11 re-
ported seven above-knee (PTFE ¼ 3) and nine below-knee
(PTFE ¼ 4) amputations after a 10-year follow-up period.
Thirteen major limb amputations were reported by Jensen
et al,12 in which there was no statistical signiﬁcance be-
tween types of graft used (Dacron ¼ 7). However, these
authors noted that surgical revascularization for critical
ischemia signiﬁcantly related to amputation rates (P <
.001). Abbott/Green et al16,17 described 10 patients (4%)
who proceeded to major limb amputation, ﬁve in each
group. However, only one patient required amputation for
graft failure, whereas all other patients required amputation
for uncontrollable local sepsis despite a patent graft. As the
Fig 4. Meta-analysis of 5-year secondary patency rate by ﬁxed-effects (a) and random-effects (b)Mantel-Haenszel (M-
H) models. CI, Conﬁdence interval; PTFE, polytetraﬂuoroethylene.
Fig 5. Risk of bias assessment.
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able to comment on limb loss.13-15
Morbidity and mortality. Abbott/Green et al16,17
documented a 6.5% overall complication rate, with car-
diac morbidity accounting for 2.2%. There was no peri-
operative mortality, and 3-year survival was 77%. This
reduced to 59.4% during 5-year follow-up. There was no
difference in morbidity or mortality between the two graft
conduits. Jensen et al12 described a 13% morbidity rate
related mainly to superﬁcial wound complications (necro-
sis, oozing, or hematoma) and a 0.7% perioperative and 9%
2-year mortality rate. There was no signiﬁcant difference in
mortality and wound, cardiac, or pulmonary complications
between the two grafts (P ¼ .22). van Det et al11 showed a
12.8% 2-year, 32.0% 5-year, and 60.7% mortality at the end
of the 10-year follow-up period for their cohort of patients.
Although there was no in-hospital mortality, two patients
died within 30 days of surgery. No other complications
were documented, and there were no differences in these
outcomes between the two graft materials. Davidovic
et al10 did not report any morbidity or mortality data. Aspreviously stated, the remaining studies included below-
knee procedures, and therefore we could not analyze
their data.
DISCUSSION
Current evidence conﬁrms that vein graft, when it is
available, is a superior choice for lower extremity arterial
bypass. Among published reports, no consensus currently
exists on which type of prosthetic graft is better, and the
surgeon’s subjective preference or previous experience
would most likely be the reason for use of one graft over
another. A Cochrane review in 2010 suggested that
Dacron grafts are at least comparable to PTFE or may
even be superior when directly compared. Since that pub-
lication, new evidence has emerged in support of the
Dacron graft.10 Some authors have also recommended
use of a vein cuff together with prosthetic material to
improve longer term patency. However, the randomized
controlled trial of Grifﬁths et al18 comparing PTFE grafts
with and without vein cuff did not reveal signiﬁcant differ-
ences in the long-term patency between those groups for
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Volume 60, Number 2 Rychlik et al 515above-knee bypasses. There are no trials reporting the use
of vein cuffs with Dacron grafts.
There remains signiﬁcant heterogeneity between all
included studies in our meta-analysis, particularly relating
to the patient population and indication for intervention,
standardized surgical technique, uniform graft size and ma-
terial for both conduits, and incorporation of best medical
therapy, especially antiplatelet or anticoagulation therapies.
Standardization of an end conclusion is therefore chal-
lenging because of these possible confounding factors,
which introduce bias and affect the strength of concluding
remarks. We have also included extracted data in relation to
above-knee procedures from three of the included publica-
tions, which permitted primary patency analysis. However,
we could not evaluate the impact of graft choice on mortal-
ity, morbidity, or limb loss rates.13-15
Three of the included studies support the use of
Dacron graft rather than PTFE in above-knee bypass pro-
cedures.10-12 Devine et al14,15 further support the use of
Dacron grafts at 36 months. These studies are also the
most recently reported in the current literature. The 1-,
2-, and 5-year primary patency rates described in the recent
publications show superiority of the Dacron graft, with
additional advantageous secondary patency rates for the
Dacron grafts. Unfortunately, the exact inﬂuence of best
medical therapy, particularly antiplatelet and anticoagula-
tion therapy, remains unclear, whereas exact anatomic
data pertaining to vessel runoff were also lacking in many
of the studies. The remaining studies, which reported no
signiﬁcant difference between the two materials, included
different graft sizes and variable anticoagulation strategies
without strict monitoring.13,16,17 The effect of newer
heparin-bonded graft conduits has also not been fully eval-
uated by this meta-analysis.
Risk of bias assessment. Selection of patients and
allocation were satisfactory in 75% of the studies. However,
blinding did not take place in any of the studies included in
this meta-analysis. Only Abbott/Green et al16,17 did not
include complete follow-up data, in which 13 patients were
lost to follow-up and there was no clear reason provided for
their exclusion. Other potential source of bias included
antithrombotic strategies, which varied between the cen-
ters and the studies included in this meta-analysis (Fig 5).
CONCLUSIONS
Despite inherent limitations due to the quality of the
included studies evaluated, our meta-analysis strongly sup-
ports use of Dacron grafts over PTFE for above-knee fem-
oropopliteal arterial bypasses. Further randomized trials
targeting standardization of confounding variables, particu-
larly graft size and best medical therapy, are warranted.
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